Loading…

The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model

IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission b...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-08, Vol.14, p.1188392-1188392
Main Authors: Dickson, Alexandria, Geerling, Elizabeth, Stone, E. Taylor, Hassert, Mariah, Steffen, Tara L., Makkena, Taneesh, Smither, Madeleine, Schwetye, Katherine E., Zhang, Jianfeng, Georges, Bertrand, Roberts, M. Scot, Suschak, John J., Pinto, Amelia K., Brien, James D.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3
cites cdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3
container_end_page 1188392
container_issue
container_start_page 1188392
container_title Frontiers in immunology
container_volume 14
creator Dickson, Alexandria
Geerling, Elizabeth
Stone, E. Taylor
Hassert, Mariah
Steffen, Tara L.
Makkena, Taneesh
Smither, Madeleine
Schwetye, Katherine E.
Zhang, Jianfeng
Georges, Bertrand
Roberts, M. Scot
Suschak, John J.
Pinto, Amelia K.
Brien, James D.
description IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.
doi_str_mv 10.3389/fimmu.2023.1188392
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7d0dafc5e0fd4e5ca39654045606dde5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7d0dafc5e0fd4e5ca39654045606dde5</doaj_id><sourcerecordid>2860619144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</originalsourceid><addsrcrecordid>eNpVksFuEzEQhlcIJKrSF-DkI4du6rW9TnxCUVSgohISLVytWXu2cbW7DrY3Fa_DkzJpIkR9sT3zzzfSr7-q3jd8IeXKXPVhHOeF4EIumma1kka8qs4arVUthVCv_3u_rS5yfuR0lJFStmfVn_stshQHZLFne3AuTFBCnKg2F2RPoWwZTAw8TnEf0pzrPboSE_qTGlmY2C7FQmWau2SkgoG5OBXCXtKwZyXBlMeQ8wFM8kI779bf7-pN_FmLq6_Nqt6uN9eCjXHOB2B_hNHf4_CuetPDkPHidJ9XPz5d32--1LffPt9s1re1U0qXGgB1b-TSYNcrxzsBxktYOgNKtA4V9aVWqJWHXrcOPF-C4oZDBx1Z5uV5dXPk-giPdpfCCOm3jRDscyGmBwupBDegXXpOFNci771CgkmjW8VVq7n2HltifTyydnM3ondIbsDwAvqyM4WtfYh723CljVScCB9OhBR_zZiLJQMdDgNMSC5ZsaJdjWmUIqk4Sl2KOSfs_-1puD0kxD4nxB4SYk8JkX8BFDy0Gg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2860619144</pqid></control><display><type>article</type><title>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</title><source>PubMed Central</source><creator>Dickson, Alexandria ; Geerling, Elizabeth ; Stone, E. Taylor ; Hassert, Mariah ; Steffen, Tara L. ; Makkena, Taneesh ; Smither, Madeleine ; Schwetye, Katherine E. ; Zhang, Jianfeng ; Georges, Bertrand ; Roberts, M. Scot ; Suschak, John J. ; Pinto, Amelia K. ; Brien, James D.</creator><creatorcontrib>Dickson, Alexandria ; Geerling, Elizabeth ; Stone, E. Taylor ; Hassert, Mariah ; Steffen, Tara L. ; Makkena, Taneesh ; Smither, Madeleine ; Schwetye, Katherine E. ; Zhang, Jianfeng ; Georges, Bertrand ; Roberts, M. Scot ; Suschak, John J. ; Pinto, Amelia K. ; Brien, James D.</creatorcontrib><description>IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2023.1188392</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>Immunology ; intramuscular vaccination ; intranasal vaccination ; SARS-CoV-2 ; vaccine efficacy ; vaccine immunogenicity ; virus transmission</subject><ispartof>Frontiers in immunology, 2023-08, Vol.14, p.1188392-1188392</ispartof><rights>Copyright © 2023 Dickson, Geerling, Stone, Hassert, Steffen, Makkena, Smither, Schwetye, Zhang, Georges, Roberts, Suschak, Pinto and Brien 2023 Dickson, Geerling, Stone, Hassert, Steffen, Makkena, Smither, Schwetye, Zhang, Georges, Roberts, Suschak, Pinto and Brien</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</citedby><cites>FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469340/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469340/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Dickson, Alexandria</creatorcontrib><creatorcontrib>Geerling, Elizabeth</creatorcontrib><creatorcontrib>Stone, E. Taylor</creatorcontrib><creatorcontrib>Hassert, Mariah</creatorcontrib><creatorcontrib>Steffen, Tara L.</creatorcontrib><creatorcontrib>Makkena, Taneesh</creatorcontrib><creatorcontrib>Smither, Madeleine</creatorcontrib><creatorcontrib>Schwetye, Katherine E.</creatorcontrib><creatorcontrib>Zhang, Jianfeng</creatorcontrib><creatorcontrib>Georges, Bertrand</creatorcontrib><creatorcontrib>Roberts, M. Scot</creatorcontrib><creatorcontrib>Suschak, John J.</creatorcontrib><creatorcontrib>Pinto, Amelia K.</creatorcontrib><creatorcontrib>Brien, James D.</creatorcontrib><title>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</title><title>Frontiers in immunology</title><description>IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.</description><subject>Immunology</subject><subject>intramuscular vaccination</subject><subject>intranasal vaccination</subject><subject>SARS-CoV-2</subject><subject>vaccine efficacy</subject><subject>vaccine immunogenicity</subject><subject>virus transmission</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksFuEzEQhlcIJKrSF-DkI4du6rW9TnxCUVSgohISLVytWXu2cbW7DrY3Fa_DkzJpIkR9sT3zzzfSr7-q3jd8IeXKXPVhHOeF4EIumma1kka8qs4arVUthVCv_3u_rS5yfuR0lJFStmfVn_stshQHZLFne3AuTFBCnKg2F2RPoWwZTAw8TnEf0pzrPboSE_qTGlmY2C7FQmWau2SkgoG5OBXCXtKwZyXBlMeQ8wFM8kI779bf7-pN_FmLq6_Nqt6uN9eCjXHOB2B_hNHf4_CuetPDkPHidJ9XPz5d32--1LffPt9s1re1U0qXGgB1b-TSYNcrxzsBxktYOgNKtA4V9aVWqJWHXrcOPF-C4oZDBx1Z5uV5dXPk-giPdpfCCOm3jRDscyGmBwupBDegXXpOFNci771CgkmjW8VVq7n2HltifTyydnM3ondIbsDwAvqyM4WtfYh723CljVScCB9OhBR_zZiLJQMdDgNMSC5ZsaJdjWmUIqk4Sl2KOSfs_-1puD0kxD4nxB4SYk8JkX8BFDy0Gg</recordid><startdate>20230816</startdate><enddate>20230816</enddate><creator>Dickson, Alexandria</creator><creator>Geerling, Elizabeth</creator><creator>Stone, E. Taylor</creator><creator>Hassert, Mariah</creator><creator>Steffen, Tara L.</creator><creator>Makkena, Taneesh</creator><creator>Smither, Madeleine</creator><creator>Schwetye, Katherine E.</creator><creator>Zhang, Jianfeng</creator><creator>Georges, Bertrand</creator><creator>Roberts, M. Scot</creator><creator>Suschak, John J.</creator><creator>Pinto, Amelia K.</creator><creator>Brien, James D.</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230816</creationdate><title>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</title><author>Dickson, Alexandria ; Geerling, Elizabeth ; Stone, E. Taylor ; Hassert, Mariah ; Steffen, Tara L. ; Makkena, Taneesh ; Smither, Madeleine ; Schwetye, Katherine E. ; Zhang, Jianfeng ; Georges, Bertrand ; Roberts, M. Scot ; Suschak, John J. ; Pinto, Amelia K. ; Brien, James D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Immunology</topic><topic>intramuscular vaccination</topic><topic>intranasal vaccination</topic><topic>SARS-CoV-2</topic><topic>vaccine efficacy</topic><topic>vaccine immunogenicity</topic><topic>virus transmission</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dickson, Alexandria</creatorcontrib><creatorcontrib>Geerling, Elizabeth</creatorcontrib><creatorcontrib>Stone, E. Taylor</creatorcontrib><creatorcontrib>Hassert, Mariah</creatorcontrib><creatorcontrib>Steffen, Tara L.</creatorcontrib><creatorcontrib>Makkena, Taneesh</creatorcontrib><creatorcontrib>Smither, Madeleine</creatorcontrib><creatorcontrib>Schwetye, Katherine E.</creatorcontrib><creatorcontrib>Zhang, Jianfeng</creatorcontrib><creatorcontrib>Georges, Bertrand</creatorcontrib><creatorcontrib>Roberts, M. Scot</creatorcontrib><creatorcontrib>Suschak, John J.</creatorcontrib><creatorcontrib>Pinto, Amelia K.</creatorcontrib><creatorcontrib>Brien, James D.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dickson, Alexandria</au><au>Geerling, Elizabeth</au><au>Stone, E. Taylor</au><au>Hassert, Mariah</au><au>Steffen, Tara L.</au><au>Makkena, Taneesh</au><au>Smither, Madeleine</au><au>Schwetye, Katherine E.</au><au>Zhang, Jianfeng</au><au>Georges, Bertrand</au><au>Roberts, M. Scot</au><au>Suschak, John J.</au><au>Pinto, Amelia K.</au><au>Brien, James D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</atitle><jtitle>Frontiers in immunology</jtitle><date>2023-08-16</date><risdate>2023</risdate><volume>14</volume><spage>1188392</spage><epage>1188392</epage><pages>1188392-1188392</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.</abstract><pub>Frontiers Media S.A</pub><doi>10.3389/fimmu.2023.1188392</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2023-08, Vol.14, p.1188392-1188392
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7d0dafc5e0fd4e5ca39654045606dde5
source PubMed Central
subjects Immunology
intramuscular vaccination
intranasal vaccination
SARS-CoV-2
vaccine efficacy
vaccine immunogenicity
virus transmission
title The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T04%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20vaccination%20route%20with%20an%20adenovirus-vectored%20vaccine%20in%20protection,%20viral%20control,%20and%20transmission%20in%20the%20SARS-CoV-2/K18-hACE2%20mouse%20infection%20model&rft.jtitle=Frontiers%20in%20immunology&rft.au=Dickson,%20Alexandria&rft.date=2023-08-16&rft.volume=14&rft.spage=1188392&rft.epage=1188392&rft.pages=1188392-1188392&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2023.1188392&rft_dat=%3Cproquest_doaj_%3E2860619144%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2860619144&rft_id=info:pmid/&rfr_iscdi=true